Bibliography
1. Berenson JR et al. A Phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed/refractory multiple myeloma. Â Clin Cancer Res 2020 May 15;26(10):2346-2353; doi: 10.1158/1078-0432.CCR-19-1899
2. Bujarski S et al. Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone.  Blood. 132:1894 (2018).
3. Sutanto C, Spektor TM, Bujarski S et al. Serum B-cell maturation antigen (sBCMA) levels as a prognostic and monitoring tool for relapsed/refractory multiple myeloma patients treated in a phase 1 trial with ruxolitinib, lenalidomide and methylprednisolone. 2020 (in preparation)
1. Chen H et al. JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression. Brit J Haematol. 2020. 188(2):283-294 (2020);
doi: 10.1111/bjh.16158
2. Chen H et al. Ruxolitinib Reverses Checkpoint Inhibition by Reducing PD-L1 Expression and Increasing Anti-tumor Effects of T cells in Myeloma. Â (Submitted)Â 2020
3. Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir I, Huang J, Daniely D, Wang C, Xu N, and Berenson JR. The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma, Blood. 134 (Supplement 1):4352 (2019)
4. Xu N, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir Y, Yu J, Huang J, Daniely D, Wang C, Chen H, and Berenson JR. The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma. Blood. 134 (Supplement 1):1824 (2019)
5. Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir I, Yu J, Huang J, Daniely D, Wang C, Xu N, and Berenson JR. Ruxolitinib Reverses Checkpoint Inhibition by Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma. Blood. 134 (Supplement 1):4402 (2019)
6. Chen H, Li M, Sanchez E, Gillespie A, Wang C, Lee T, Vardanyan S, Nosrati J, Cao J, Zahab M, Mehta P, Garzio G, Tang G, and Berenson JR. Increased Alternative Macrophage-2 (M2) Polarization with Trib1 Gene over Expression in Myeloma Patients with Progressive Disease and Jak2 Inhibitors Reduce M2 Polarization. Blood 126(23):1011 (December 2015)
7. Sanchez E, Li M, Wang C, Mehta P, Tang G, Chen H, and Berenson JR, “Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Standard of Care Agents in Human Multiple Myeloma (MM) Cell Lines and Xenograft Models,†AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1339 (2016)
8. Berenson JR, “Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 in Combination with Active Myeloma Agents in Vitro and in Vivo,†International Myeloma Workshop, India, Abstract Book p e71 (March 2017) DOI:https://doi.org/10.1016/j.clml.2017.03.089
9. Sanchez E, Li M, Wang C, Tanenbaum EJ, Patil S, Soof CM, Schlossberg R, Yachar MA, Hekmati T, Porter A, Tang G, Chen H, and Berenson JR, “Anti-Myeloma Effects of the Selective JAK1 Inhibitor INCB052793 Using a Platform Study Utilizing the LAGg-1A Multiple Myeloma Xenograft Model,†Blood. 130:5393 (2017)
10. Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Cao J, Hekmati T, Tanenbaum EJ, Zahab B, Wang CS, Tang GY, Xu N, and Berenson JR, “The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids,†Blood. 132:1910 (2018)
11. TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target .Hong Liu, Samantha Tamashiro, Stavroula Baritaki, Manuel Penichet, Youhua Yu, Haiming Chen, James Berenson, Benjamin Bonavida Clin Lymphoma Myeloma Leuk. Author manuscript; available in PMC 2013 Oct 19. Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3): 155–163. Published online 2012 Mar 21. doi: 10.1016/j.clml.2012.01.006